Niagen Bioscience (FRA:OCD1) 5-Year EBITDA Growth Rate: 0.00% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:OCD1 Niagen Bioscience Inc FRA:OCD1
68 GF Score
Price €2.60
GF Value €3.77
! 2 Warning Signs
View Full Analysis

What is Niagen Bioscience 5-Year EBITDA Growth Rate?

Niagen Bioscience FRA:OCD1 +9.24% 68 5-Year EBITDA Growth Rate is 0.00% as of Jun. 2026. GuruFocus rates FRA:OCD1 with a GF Score™ of 68/100 and a GF Value™ of €3.77. The stock has 2 warning signs investors should review.

Niagen Bioscience's EBITDA per Share for the three months ended in Jun. 2026 was €0.02.

During the past 12 months, Niagen Bioscience's average EBITDA Per Share Growth Rate was -45.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Niagen Bioscience was 48.60% per year. The lowest was -143.40% per year. And the median was -0.85% per year.

Niagen Bioscience  (FRA:OCD1) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Niagen Bioscience 5-Year EBITDA Growth Rate Related Terms

FRA:OCD1 vs CAMP, ALEC, ELDN: 5-Year EBITDA Growth Rate Comparison

For the Packaged Foods subindustry, Niagen Bioscience's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Niagen Bioscience 5-Year EBITDA Growth Rate vs Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Niagen Bioscience's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Niagen Bioscience's 5-Year EBITDA Growth Rate falls into.


FRA:OCD1
68GF Score
Niagen Bioscience Inc FRA:OCD1
5-Year EBITDA Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Niagen Bioscience 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

What does a 5-Year EBITDA Growth Rate of 0.00% mean?
Niagen Bioscience (FRA:OCD1) has a 5-Year EBITDA Growth Rate of 0.00% as of Jun. 2026. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Niagen Bioscience and its competitors.
Is Niagen Bioscience's 5-Year EBITDA Growth Rate too high?
Niagen Bioscience's current 5-Year EBITDA Growth Rate is 0.00%. Overall, Niagen Bioscience has a GF Score™ of 68/100, reflecting its overall financial health beyond just this single metric.
How does Niagen Bioscience's 5-Year EBITDA Growth Rate compare to CAMP and ALEC?
Niagen Bioscience's 5-Year EBITDA Growth Rate of 0.00% can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year EBITDA Growth Rate for a Consumer Packaged Goods company?
A good 5-Year EBITDA Growth Rate depends on the Consumer Packaged Goods industry context. However, 5-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year EBITDA Growth Rate mean?
A high 5-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Niagen Bioscience and its competitors. Niagen Bioscience's current 5-Year EBITDA Growth Rate is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Niagen Bioscience stock overvalued right now?
Niagen Bioscience (FRA:OCD1) has a current 5-Year EBITDA Growth Rate of 0.00%. The stock's GF Value™ is €3.77, compared to a current price of €2.60 — trading 31% below its estimated fair value. The current 5-Year EBITDA Growth Rate is 0.00%. Niagen Bioscience's overall GF Score™ is 68/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year EBITDA Growth Rate calculated?
5-Year EBITDA Growth Rate is calculated from a company's financial statements. For Niagen Bioscience (FRA:OCD1), the current 5-Year EBITDA Growth Rate is 0.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Niagen Bioscience (FRA:OCD1) Overvalued in 2026?

Based on GuruFocus' analysis, Niagen Bioscience stock appears to be undervalued. The current stock price of €2.60 is trading 31% below its estimated GF Value™ of €3.77.

Key valuation signals for FRA:OCD1:

  • 5-Year EBITDA Growth Rate: 0.00%
  • GF Value™: €3.77 vs. price of €2.60 (31% below fair value)
  • GF Score™: 68/100 with 2 warning signs

No single metric tells the full story. See the FRA:OCD1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Niagen Bioscience Business Description

Other Exchanges NAGE:USAOCD1:Germany
Address 10900 Wilshire Boulevard, Suite 600, Los Angeles, CA, USA, 90024
Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.
68GF Score

Get the complete analysis for FRA:OCD1

5-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.60
Price
€3.77
GF Value